Lihui Xu
About Lihui Xu
Lihui Xu serves as the Director of Antibody Engineering at Mythic Therapeutics, Inc. since 2022, bringing extensive experience in antibody design and development, including bispecific antibodies and antibody-liposome conjugates.
Work at Mythic Therapeutics
Lihui Xu serves as the Director of Antibody Engineering at Mythic Therapeutics, Inc. since 2022. In this role, he focuses on advancing antibody engineering strategies to support the company's therapeutic initiatives. His expertise in antibody library design and selection plays a crucial role in the development of innovative treatments. Mythic Therapeutics is located in Waltham, Massachusetts, where Xu contributes to the company's mission of creating effective biotherapeutics.
Previous Experience in Antibody Engineering
Prior to his current position, Lihui Xu held significant roles in various organizations. He worked at Merrimack Pharmaceuticals as Associate Director and Antibody Technology Team Leader from 2003 to 2016. He also served as Associate Director of Biotherapeutics Discovery at Palleon Pharmaceuticals from 2016 to 2021. His earlier experience includes positions at the Massachusetts Institute of Technology and the University of Pennsylvania, where he developed foundational skills in antibody engineering.
Education and Expertise
Lihui Xu possesses extensive expertise in antibody engineering, particularly in the design, construction, and selection of antibody libraries. He is skilled in the humanization of mouse antibodies to meet therapeutic design criteria. His specialization includes the discovery of bispecific antibodies and antibody-liposome conjugates, along with proficiency in affinity maturation and stability optimization of antibodies. Xu is also experienced in antibody discovery methodologies such as yeast display and hybridoma technology.
Research Contributions
Lihui Xu has contributed to significant research in the field of antibody engineering. Notably, he was involved in a journal article discussing MYTX-011, a pH-dependent anti-cMET antibody-drug conjugate. This work focused on enhancing payload delivery to cMET expressing tumor cells, showcasing his commitment to advancing therapeutic strategies in oncology. His contributions reflect a strong emphasis on innovation in biotherapeutics.